We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HGEN
2801
DELISTED
HUMANIGEN, INC.
HGEN
| $272K | ﹤0.01% |
45,803
+2,143
| +5% | +$30.1K |
|
2802
Bolt Biotherapeutics
BOLT
$7.78M
| $271K | ﹤0.01% |
1,073
+413
| +63% | +$117K |
|
|
MRLN
2803
DELISTED
Marlin Business Services Corp
MRLN
| $271K | ﹤0.01% |
12,204
-180
| -1% | -$4.04K |
|
|
DRRX
2804
DELISTED
DURECT Corp
DRRX
| $270K | ﹤0.01% |
21,132
+221
| +1% | +$3K |
|
2805
FS KKR Capital
FSK
$3.44B
| $270K | ﹤0.01% |
12,272
| – | – |
|
2806
Village Super Market
VLGEA
$639M
| $270K | ﹤0.01% |
12,444
+277
| +2% | +$6.24K |
|
2807
Oil-Dri
ODC
$1.34B
| $268K | ﹤0.01% |
15,328
+94
| +0.6% | +$1.65K |
|
2808
Black Diamond Therapeutics
BDTX
$112M
| $266K | ﹤0.01% |
31,393
+1,075
| +4% | +$10.6K |
|
|
CMBM
2809
DELISTED
Cambium Networks
CMBM
| $266K | ﹤0.01% |
7,363
+518
| +8% | +$20.5K |
|
2810
South Plains Financial
SPFI
$841M
| $266K | ﹤0.01% |
10,897
-50
| -0.5% | -$1.16K |
|
|
MSON
2811
DELISTED
Misonix Inc
MSON
| $266K | ﹤0.01% |
10,530
-353
| -3% | -$8.74K |
|
2812
Spruce Power Holding Corp
SPRU
$39.9M
| $265K | ﹤0.01% |
5,386
-29
| -0.5% | -$1.55K |
|
|
CCRD
2813
DELISTED
CoreCard
CCRD
| $264K | ﹤0.01% |
6,510
-15
| -0.2% | -$534 |
|
2814
eGain
EGAN
$201M
| $264K | ﹤0.01% |
25,861
+670
| +3% | +$7.57K |
|
2815
Teekay
TK
$985M
| $264K | ﹤0.01% |
72,051
+2,382
| +3% | +$7.5K |
|
|
EIGR
2816
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $264K | ﹤0.01% |
1,318
+36
| +3% | +$8.56K |
|
2817
Capital Bancorp
CBNK
$615M
| $260K | ﹤0.01% |
10,787
+67
| +0.6% | +$1.5K |
|
2818
iShares Russell 2000 Growth ETF
IWO
$15.1B
| $260K | ﹤0.01% |
886
-181
| -17% | -$54.4K |
|
|
INFI
2819
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $259K | ﹤0.01% |
75,828
+4,289
| +6% | +$13.2K |
|
|
FYBR
2820
DELISTED
Frontier Communications
FYBR
| $258K | ﹤0.01% |
+9,251
| New | +$275K |
|
2821
LegalZoom.com
LZ
$988M
| $258K | ﹤0.01% |
+9,759
| New | +$343K |
|
2822
Viemed Healthcare
VMD
$371M
| $258K | ﹤0.01% |
46,488
+436
| +0.9% | +$2.84K |
|
|
RXDX
2823
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $258K | ﹤0.01% |
10,894
+525
| +5% | +$12.4K |
|
2824
BeyondSpring
BYSI
$35.8M
| $257K | ﹤0.01% |
16,290
+1,345
| +9% | +$24.2K |
|
2825
Foghorn Therapeutics
FHTX
$360M
| $257K | ﹤0.01% |
18,474
+2,815
| +18% | +$31.2K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.